Secondary Myelofibrosis Recruiting Phase 2 Trials for Decitabine (DB01262)

IndicationStatusPhase
DBCOND0030964 (Secondary Myelofibrosis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04282187Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsTreatment